Objective
We characterized the ability of mometasone furoate/ formoterol (MF/F) combination to improve asthma control in adults/adolescents inadequately controlled on low-, medium-, and high-dose inhaled corticosteroids (ICS).
Methods
Changes from baseline to endpoint (last evaluable visit) in Asthma Control Questionnaire (ACQ) scores were assessed in subjects from 3 Phase III trials (low-[n=746], medium-[n=781], and high-dose [n=728] previous ICS use). The ACQ categorizes asthma symptoms and use of rescue-medication using a 7-point scale (0=totally controlled, 6=severely uncontrolled). In two placebo controlled trials, subjects were randomized to receive MF/F (100/10μg or 200/10μg), MF (100μg or 200μg), F (10μg), or placebo (26 weeks; all twice-daily [BID] via metereddose inhaler [MDI] ); In a non-placebo controlled trial, subjects were randomized to receive MF/F 200/10μg, MF/F 400/10μg, or MF 400μg (12 weeks; all BID via MDI).
Results
Baseline ACQ scores (1.23-1.38 (MF/F 100/10μg study), 1.41-1.47 (MF/F 200/10μg study), and 1.83-1.87 (MF/F 200/10 and 400/10μg study) indicated that subjects in all trials were not well controlled (<0.75) on ICS monotherapy. MF/F yielded ACQ improvements , and deteriorations with F 10μg (+0.07; +0.11) and placebo (+0.24; +0.14). MF/F 400/10μg improved asthma control by -0.51 compared with -0.33 for MF 400μg monotherapy. Improvements for MF/F at all doses achieved minimal importance difference of ≥0.5 point increase.
Conclusion
MF/F showed clinically important improvement in asthma control at all strengths and was better than MF, F and placebo.
